Alcohol increases the incidence of oral and esophageal cancers, and smoking multiplies that risk
Reducing or stopping alcohol consumption decreases the risk of oral and esophageal cancers. Alcohol undeniably increases the risk of these cancers, and smoking multiplies that risk.

The International Agency for Research on Cancer (IARC) assessed the impact of alcohol consumption on the risk of seven different cancers. Its report was published in the prestigious New England Journal of Medicine.
According to the report, there is strong scientific evidence that reducing or stopping regular alcohol consumption reduces the risk of oral and esophageal cancers.
“A dry January is not enough, but reducing alcohol consumption permanently can significantly reduce the risk of all alcohol-related cancers, and at the same time also alcohol-related problems and other alcohol-related diseases,” says Professor Emeritus Mikko Salaspuro.
Mikko Salaspuro contributed to compiling the report. He has been studying the mechanisms of alcohol-related cancers for more than 30 years at the University of Helsinki and at HUS. Under Salaspuro's guidance, 11 doctoral theses and 62 scientific publications have been completed on the subject. These studies played a key role in the preparation of the report.
Alcohol is converted into a carcinogen in the body
Alcohol increases the risk of cancer when bacteria and yeasts in the body convert alcohol in the digestive tract into the cancer-causing acetaldehyde. Acetaldehyde is a DNA-binding compound that can cause carcinogenic mutations and inhibit the repair of chromosomal damage. Alcohol in itself is not carcinogenic.
Mikko Salaspuro's research team used genetic studies to establish a causal link between acetaldehyde and upper gastrointestinal cancers, and to investigate the factors that regulate acetaldehyde levels in saliva and colon contents during alcohol consumption.
Alcohol enters the intestines through the bloodstream. However, the effects of alcohol on the intestines are individual, and the report concludes that evidence for the cancer risk-reducing effect of stopping alcohol consumption is weak. According to the report, there is no evidence of the role of acetaldehyde in the mechanisms of liver and breast cancer development, but these are affected by alcohol in a roundabout way.
Smoking multiplies the risk of alcohol-induced cancer
The report also took into account Finnish studies on the interaction between regular smoking and alcohol: oral microbes produce twice as much acetaldehyde from ethanol in smokers as they do in non-smokers.
Tobacco smoke contains acetaldehyde, and Mikko Salaspuro's research team has shown that the acetaldehyde in tobacco smoke is partially soluble in saliva. Oral acetaldehyde exposure is seven times higher in alcohol drinkers and smokers than in alcohol drinkers who do not smoke.
The report states that alcohol and tobacco also cause a similar process of acetaldehyde formation in the pharynx and larynx. People who quit drinking alcohol have a 31% lower relative risk of developing laryngeal cancer compared to regular drinkers.
The authors of the report were invited by the International Agency for Research on Cancer (IARC) to review the scientific evidence on the risk and prevention of alcohol-related cancers. A book on the subject is also being published. The IARC is an international research institute under the World Health Organization (WHO) that brings together cancer researchers to study the incidence of cancer and find ways to prevent it.
In 2020, an estimated 741,300 people were diagnosed with alcohol-related cancer.
Link to the research article:
The IARC Perspective on Alcohol Reduction or Cessation and Cancer Risk
Contacts
Mikko SalaspuroProfessor EmeritusUniversity of Helsinki
Tel:+358 50 051 1689mikko.salaspuro@helsinki.fiVeronique Terrasse
Interview requests from international researchers
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Gips räcker vid frakturer på mediala humerusepikondylen vid armbågsleden hos barn9.9.2025 09:55:56 EEST | Pressmeddelande
I en nyligen publicerad studie framgick det att gipsning som behandling vid frakturer på mediala humerusepikondylen hos barn är en lika effektiv behandlingsform som operation. De resultat som man nu fått stöder gipsbehandling som primär behandlingsform och behandlingen kan förenhetligas på riksnivå.
Kipsi riittää lasten kyynärnivelen koukistajalisäkkeen murtumissa9.9.2025 09:55:56 EEST | Tiedote
Juuri julkaistussa tutkimuksessa selvisi, että lasten kyynärnivelen koukistajalisäkkeen murtumien hoidossa kipsaus on yhtä tehokas hoitomuoto kuin leikkaus. Nyt saadut tulokset tukevat kipsihoidon käyttöä ensisijaisena hoitomuotona, ja hoitoa voidaan yhtenäistää kansallisesti.
Den nyaste ekonomiska prognosen för hela 2025: HUS är på väg att uppnå sina ekonomiska mål för 20258.9.2025 12:09:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade på sitt möte verksamheten och ekonomin i januari–juli samt den nyaste årsprognosen för hela 2025. HUS-sammanslutningens operativa resultat beräknas uppvisa ett överskott på 0,1 miljoner euro. Sammanslutningens styrelse fastställde också investeringsplanen och investeringsprogrammet för de kommande åren.
Koko vuoden 2025 uusin talousennuste: HUS pääsemässä vuonna 2025 taloudellisiin tavoitteisiinsa8.9.2025 12:09:48 EEST | Tiedote
HUSin yhtymähallitus käsitteli kokouksessaan tammi–heinäkuun taloutta sekä uusinta koko vuoden 2025 vuosiennustetta. HUS-yhtymän operatiivisen tuloksen ennustetaan päätyvän 0,1 miljoonaa euroa ylijäämäiseksi. Yhtymähallitus vahvisti myös tulevien vuosien investointisuunnitelman ja -ohjelman.
Förebyggande av RS-virusinfektion hos spädbarn inleds på HUS sjukhus3.9.2025 14:17:24 EEST | Pressmeddelande
RS-virus (respiratory syncytial virus, RSV) är den vanligaste orsaken till luftvägsinfektioner som kräver sjukhusvård hos små barn. HUS erbjuder en antikropp som utvecklats mot RS-virus, det vill säga nirsevimab åt nyfödda och barn under ett år som hör till riskgrupperna.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom